MRK  Merck & Company Inc.

Exchange

NYSE

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

165.66B

Vuru Grade

55.06/100

Current Price

$58.64
+1.115 (+1.938%)

Growth Price

$34.60
Overvalued by 40.99%

Stability Price

$19.99
Overvalued by 65.91%

Company Metrics

  • 15.234 P/E
  • 3.925 P/S
  • 3.406 P/B
  • 3.849 EPS
  • 12.10% Cash ROIC
  • 0.84 Cash Ratio
  • 1.8 / 3.1% Dividend
  • 9.59M Avg. Vol.
  • 2.83B Shares
  • 165.66B Market Cap.

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Zacks Rating on Merck & Company, Inc.
Insider Trading Report - 6 hours ago
As much as 13 analysts have advised buy on Merck & Company, Inc. (NYSE:MRK) with an average broker rating of 2.08. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation is Neutral on the company.
Merck & Co., Inc. (MRK) Releases FY15 Earnings Guidance
Junior College - 22 hours ago
The company provided earnings per share (EPS) guidance of $3.45-3.55 for the period, compared to the Thomson Reuters consensus estimate of $3.44, ARN reports.
Are Merck Earnings Enough? - 24/7 Wall St.
Earnings Whispers - Merck & Co., Inc. (MRK) To Report Q2 Earnings Today - Bidness ETC
Active Stocks in Review: Merck & Co. Inc. (NYSE:MRK), Magnum Hunter Resources ...
wsnewspublishers - Jul 29, 2015
Merck & Co., known as MSD outside the United States and Canada, recently declared that Pamela J. Craig, stepped down chief financial officer of Accenture, and Dr.
Merck & Co., Inc. (MRK) Issues FY15 Earnings Guidance
sleekmoney - 16 minutes ago
Merck & Co. logo Merck & Co., Inc. (NYSE:MRK) updated its FY15 earnings guidance on Tuesday. The company provided EPS guidance of $3.45-3.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.44, MarketBeat.
Merck & Co. Lifted to Strong-Buy at Vetr Inc. (MRK) - Watch List News
ABLYNX SIGNIFICANTLY EXPANDS ITS IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO ...
MarketWatch - Jul 22, 2015
"The expansion of this ongoing collaboration with Ablynx allows us to increase our ability to evaluate the potential of more immune checkpoint targets for the treatment of cancer.
Merck & Co. Inc. (MRK) Closes 1.77% Up on the Day for July 29
Equities.com - 15 hours ago
Dow Jones component Merck & Co. Inc. (MRK) saw its stock move 1.77% to $58.54, representing a per-share move of $1.02, on volume of 12.62 million shares for Wednesday.
Active Stocks Investor's Alert: Bank of America Corporation (NYSE:BAC), Merck ...
wsnewspublishers - 1 hour ago
The company, through its auxiliaries, operates through Consumer and Business Banking; Consumer Real Estate Services; Global Wealth and Investment Administration; Global Banking; Global Markets; and Other segments.
Active Stocks Trader's Buzzers: Merck & Co. Inc. (NYSE:MRK), MetLife, Inc ...
wsnewspublishers - Jul 28, 2015
Merck & Co., known as MSD outside the United States and Canada, declared that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the ...
Shares of Merck & Company, Inc. (NYSE:MRK) Sees Large Inflow of Net Money Flow
Money Flow Index - Jul 27, 2015
Merck & Company, Inc. (NYSE:MRK) had a weak trading session and its shares were last down at $57.41, down -0.66% or -1.14 points.
Allergan PLC On A Roll; Buys Merck & Co. Migraine Drug Rights
Bidness ETC - Jul 8, 2015
Allergan PLC (NYSE:AGN) announced on Tuesday it has entered into an agreement with Merck & Co., Inc. (NYSE:MRK), under which it would acquire exclusive global rights to two of Merck's migraine drugs currently in experimental stages, MK-1602 and ...
Merck & Co. Inc. (NYSE:MRK) and Allergan plc (AGN) Signs Into an Contract ... - StreetWise Report
Merck & Co., Inc. (NYSE:MRK) Sells Its Migraine Drugs To Allergan PLC (NYSE ... - USMarketsDaily (blog)